We recently had a chance to sit down with Chiasma Inc.’s Senior VP of Clinical Development & Medical Affairs, Dr. Bill Ludlam, to discuss his career and his work in rare diseases. Dr. Ludlam played an integral role in Chiasma’s acquisition of the first and only FDA approval for oral somatostatin analog (SSA) octreotide, called MYCAPSSA. We discussed the influences that drive Chiasma as an organization and Dr. Ludlam personally, as well as the processes that contributed to the development of MYCAPSSA. Don’t miss this engaging conversation.